Barcelona based Biorce, a health AI company working to modernise clinical trial design and execution, has closed a $52 million Series A funding round as it accelerates its mission to make drug development faster, more reliable, and more patient centric. The round brings Biorce’s total funding to more than $60 million and marks a major milestone for the young company as it expands beyond Europe and deepens its presence in the United States.
The financing includes new backing from DST Global Partners, alongside increased participation from existing investors Norrsken VC and YZR Capital. Mustard Seed Maze also joined the round, while a group of prominent angel investors, including Arthur Mensch, Albert Nieto, Paulo Rosado, and Nik Storonsky, further strengthened the company’s investor base.
Tackling inefficiencies in clinical trials
Clinical trials remain one of the most complex and costly stages of drug development. Protocol amendments are common and often unavoidable, yet they regularly slow progress and inflate budgets. Each amendment can pause patient recruitment for weeks and add hundreds of thousands of euros in additional costs. These delays are frequently driven by challenges in demonstrating trial design decisions clearly enough for regulators such as the FDA and EMA.
Biorce was founded to address this exact problem. The company is building AI infrastructure that helps pharmaceutical and biotech teams design stronger trial protocols from the outset, reducing the likelihood of errors, delays, and regulatory pushback later in the process.
Aika as the core intelligence layer
At the heart of Biorce’s offering is Aika, an AI native platform designed specifically for clinical trial design and preparation. Built on data from approximately one million historical clinical trials, Aika analyses patterns, outcomes, and risks to help teams anticipate issues before trials begin.
By supporting more robust protocol justification and decision making, the platform aims to reduce the need for amendments and shorten preparation timelines. This allows sponsors and research organisations to move more quickly into patient recruitment while maintaining scientific rigour and safety standards.
Broad applicability across therapies
A key differentiator for Biorce is that Aika is therapy agnostic. The platform is already being used across multiple therapeutic areas, including oncology, neurology, and rare diseases. This flexibility allows Biorce to scale its technology across a wide range of clinical programmes rather than being confined to a single disease area.
According to CEO Pedro Coelho, the motivation behind the company is deeply rooted in impact. He noted that inefficiencies in clinical trials do not just affect budgets, they delay patient access to potentially life changing treatments. Biorce’s goal is to ensure that promising therapies reach patients sooner by making trials more predictable and efficient.
Expansion into the US market
With fresh capital secured, Biorce is preparing for its next phase of growth. The company plans to expand its workforce and open a new development and R and D hub in Austin, Texas. The US expansion is intended to support closer collaboration with American pharmaceutical companies, regulators, and research organisations.
Looking ahead to early 2026, Biorce also plans to broaden Aika’s capabilities beyond protocol design. New modules are in development to support contract management, negotiation, budget planning, and operational execution, creating a more comprehensive intelligence layer across the full clinical trial lifecycle.
As regulatory scrutiny increases and development timelines come under pressure, Biorce is positioning itself as a critical infrastructure provider for a faster and more resilient clinical research ecosystem.